本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
MELBOURNE, Australia, Oct. 31, 2024 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a globally leading commercial vehicle manufacturer, has recently completed a battery endurance and mileage challenge of traveling 555 kilometers in a single full charge in Australia, promoting green mobility with advanced solutions for the transformation of public transport.  Think Eco, Move Green: Yutong Bus Completes Battery Mileage Challenge in Australia, Promotes Electric Transformation of Public Transport with Groundbreaking Technology Platform A Yutong C12E fully electric bus that has been operating for two and a half years successfully traveled 285 kilometers from suburb Melbourne, Preston, to Kiama roundtrip with 50 percent of battery level and power consumption at 0.63kWh/km. It traveled through diverse road conditions, including city roads, highways and mountain roads. "In the electrification transformation of public transformation, there are many challenges and bottlenecks including mileage limitation, battery safety, charging efficiency, operation reliability, as well as cost efficiency, that we need to tackle in developing pure electric buses. Yutong is committed to providing green mobility solutions through continuous technological and product innovation with our aspiration of 'Think Eco, Move Green," said Kent Chang, CEO of Yutong Asia-Pacific. The C12E is coupled with the Yutong Electric Architecture ("YEA") technology platform, which was released in September in the Asia-Pacific market as the industry's first EV-specific platform integrating software and hardware that's evolvable and expandable. YEA boasts the capability to develop various new energy and commercial vehicle products that can adapt to a wide range of travel scenarios and bring customers more economical, durable, and convenient solutions: More economical: with a 10 percent longer range and a 20 percent reduction in operating costs compared to industry peers; More durable: ensures safe and stable operation with uptime reaching 99 percent and battery lifespan of up to 1.5 million kilometers; More convenient: intelligent features to empower management with round-the-clock reliability. Yutong YEA Green Exploration Journey Launching Event in Melbourne, Australia. In the meantime of YEA technology platform's release, Yutong Bus also hosted Green Travel Week in Brisbane, underscoring the significance of sustainable transportation and community involvement. The purpose of this event is to enhance public awareness of green transportation options, such as electric vehicles, contribute to building a sustainable planet. It also intends to convey Yutong Bus's philosophy, leveraging innovative technology to extend the benefits of green transit to everyone globally, to local stakeholders. Supported by the Brisbane City Council, the initiative inspired citizens to embrace eco-friendly travel options.
e& completes acquisition of controlling stake in PPF Telecom and 100% acquisition of GlassHouse, expanding its footprint to 38 countries ABU DHABI, UAE, Oct. 31, 2024 /PRNewswire/ -- e& today announced its Q3 2024 consolidated financial results, reporting consolidated revenue of AED 14.4 billion, growing 10 per cent year-over-year in constant currency, while consolidated revenues for the first nine months of year 2024 recorded AED 42.7 billion, growing 9 per cent YoY, reflecting continued growth across most verticals. e& GCEO, Hatem Dowidar e& completed an important milestone by closing the transaction of PPF Telecom that will enhance the group portfolio diversification while it continues to grow its digital services across enterprise solutions, fintech, and media and entertainment sectors. This diversification will allow it to pursue its strategic ambition of transitioning to a global technology player. e&'s total subscriber base witnessed a YoY increase of 6 per cent, reaching 177.3 million. The total number of e& UAE subscribers reached 14.7 million, representing a YoY growth of 5 per cent. Financial Highlights Q3 2024 Q3 2023 9M 2024 9M 2023 Revenue AED 14.4 billion AED 13.4 billion AED 42.7 billion AED 40.0 billion Net Profit AED 3 billion AED 3 billion AED 8.5 billion AED 7.7 billion EBITDA AED 6.5 billion AED 6.9 billion AED 19.4 billion AED 19.6 billion Earnings per Share AED 0.34 AED 0.34 AED 0.97 AED 0.88 Hatem Dowidar, Group Chief Executive Officer, e&, said: "e& continued its strong momentum in the first nine months, with consolidated revenue growing 9 per cent in constant currency to AED 42.7 billion. We scaled up e&'s telecom footprint to 20 countries, bringing our overall reach to 38 markets. This growth, coupled with our solid performance in both local and international markets, drove our consolidated net profit to reach AED 8.5 billion growing 10 per cent during the first nine months. Furthermore, consolidated EBITDA reached AED 19.4 billion, resulting in EBITDA margin of 45 per cent, while our telecom EBITDA margin remained resilient at 49%". "Now that we have completed the acquisition of a controlling stake in PPF Telecom Group, we look forward to the opportunities that will arise as we expand our global horizon, impacting the lives of over 1 billion people across the Middle East, Asia, Africa, and now Central and Eastern Europe—marking our first operational foothold in Europe. By combining our expertise with PPF Telecom's strong local presence, we're well-positioned to drive digital transformation and empower societies across this region," added Dowidar. He concluded, "e& remains dedicated to championing the UAE's leadership vision as the country continues to advance its digital agenda as a role model of digitalisation. Our investment in cutting-edge infrastructure and strategic partnerships will ensure that we continue to deliver futuristic solutions and digital services that drive sustainable progress and transformation." Media Contacts – Nancy Sudheer, Senior Manager at e&, nsudheer@eand.com e& Q3 2024 Infographic
SHANGHAI, Oct. 30, 2024 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, announced it has entered into an official partnership for the new FIFA Club World Cup™. The announcement was made today at a special event at Shanghai Tower attended by FIFA President Gianni Infantino, FIFA Secretary General Mattias Grafström, and Hisense Group Chairman Jia Shaoqian. Speaking at the partnership launch, FIFA President Gianni Infantino said: "We are delighted to welcome Hisense, a global market-leading brand, as an Official Partner of the FIFA Club World Cup 2025™. Hisense's commitment to innovation and technology aligns with our vision for this tournament, which will bring together the 32 best teams from around the world for an unforgettable celebration of our game that will revolutionise club football." "This partnership will offer fans unique ways to engage with the tournament, both on and off the pitch, while laying a technological and innovation-led foundation for the FIFA Club World Cup™ to flourish." The new FIFA Club World Cup 2025™ will unite the world's 32 top clubs every four years. The partnership with this inaugural edition of the tournament will provide the perfect platform for Hisense to further grow its global brand among fans of the world's most popular sport and club teams, and to showcase the state-of-the-art technology and appliances with Hisense TVs to be visible across the tournament. Hisense Group Chairman Jia Shaoqian added: "We are proud to be an Official Partner of the FIFA Club World Cup 2025™, which is a competition among the top clubs from all six confederations, representing a dialogue between champions, a collision of first-class excellence. This perfectly aligns with Hisense's pursuit of the champion spirit and our latest corporate goal to build a world-class enterprise and brand." "As the pioneer in AI televisions, Hisense's newly launched AI TV series is a perfect match for the FIFA Club World Cup™. The technological foundation of Hisense AI TV is the independently developed Xinghai large model, which supports continuous smart upgrades across various appliance categories, significantly enhancing the user experience and market competitiveness. Together with FIFA, Hisense will present the best Club World Cup™ for global audiences." Hisense aims to build a world-class enterprise and brand with a continued focus on top-tier sports assets. By officially signing on as an Official Partner for the FIFA Club World Cup 2025™, the planet's brand-new premier club competition, Hisense is advancing its sports marketing strategy and accelerating its globalisation efforts. Hisense has been a global partner for two consecutive FIFA World Cups™ and three UEFA European Championships. The company is striving for the intelligent development of its products, crossing from TV, Laser TV, air conditioners, and refrigerators. In TV product line, Hisense has introduced a 100-inch TV equipped with an AI picture quality chip, providing users with an immersive viewing experience. With its refrigerators and air conditioner products, Hisense's ConnectLife platform supports the interconnectivity of smart home appliances, enabling seamless collaboration among household devices. The collaboration with FIFA underscores Hisense's commitment to delivering pioneering home appliance technology in the pursuit of improving everyday life, with innovative products and technologies in enhancing the viewing experiences for fans worldwide and making football more accessible and more engaging for all. About Hisense Hisense is a leading global home appliance and consumer electronics brand. According to Omdia, Hisense ranked No. 2 globally for TV shipments and No. 1 in 100" TVs in both 2023 and H1 2024. The company has expanded quickly to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.
沙特阿拉伯利雅德2024年10月30日 /美通社/ -- Future Minerals Forum (FMF) 將於 2025 年 1 月舉辦第四屆 International Geological Surveys 和首屆 Centers of Excellence 會議。FMF 是世界領先的礦產聚會，由沙特阿拉伯工業和礦產資源部召開，作為促進礦產業利益相關者之間的合作平台。 International Geological Surveys Meeting International Geological Survey 和 Center of Excellence 會議將於 1 月 14 日在 King Abdulaziz 國際會議中心舉行。這兩次會議都是國際金融基金會部長圓桌會議的一部分，匯聚超過 200 間政府和國際機構。 第一次在 2024 年舉行的國際地質調查會議，聚集了來自世界各地的地質調查領袖。與會者包括從非洲至西亞和中亞超級地區的地質調查領袖，也來自各大地質調查局的數據庫成員，例如美國地質調查局 (US Geological Survey)，英國地質調查局 (British Geological Survey)，法國的 BRGM 和芬蘭的 GTK。 會議的目標是： 在超級地區建立地質測量的能力，以吸引更多勘探投資。 運用最新的數碼技術和人工智能，以更精確地定位礦產，並向投資者和更廣泛的公眾提供地質資訊。 建立區域卓越中心，以推動創新、技能發展和新科技的部署。 Al-Mudaifer 表示：「隨著礦產資源耗盡，對勘探投資不足，並且沒有新的重大發現，現在是最重要的時刻，讓地質學成為焦點，並召集專家一起尋找尋找新礦床和開發能力的方法。」 他補充說：「如果不向投資者提供對礦物位置的準確識別、準確的確定性數據，以及可靠的地質資訊，全球有可能缺乏所需材料以滿足與日俱增的需求。」 FMF 還將召開首屆卓越中心會議，匯聚來自世界各地的機構、大學和領先專家，以支持建立區域卓越中心網絡。這項計劃旨在建立超級區域的能力，專注於科技培育、加速和大規模部署，同時確保當地一直處於在全球礦產和資源創新的最前線。
*Extensive collaboration expected in AI-powered products and systems••• including possible joint venture & share swap*MoU will also see Sunway tapping the talent and innovation of PhnyX Lab, the Silicon Valley-based AI research and development arm of SK Networks*SK Networks, "We'll focus on boosting the Malaysian market and maximizing synergy between the two companies to drive greater corporate value." SEOUL, South Korea, Oct. 30, 2024 /PRNewswire/ -- SK Networks, a company steering the growth of its subsidiaries and scaling future value through AI-driven innovations, is ramping up its strategic collaboration with Sunway Group, a leading conglomerate in Southeast Asia with core interests in real estate, construction, healthcare, education, leisure and hospitality sectors. SK Networks is ramping up its strategic collaboration with Sunway Group. Executives from both sides, including SK Networks President & CEO Hojeong Lee(right), President & COO Sunghwan Choi(left) and Sunway Group CEO of Digital and Strategic Investments Evan Cheah pose for a commemorative photo to mark the occasion. SK Networks (CEO: Hojeong Lee) announced on October 30 that it had inked a Memorandum of Understanding (MoU) with Sunway to establish a wide-ranging partnership encompassing both companies and their subsidiaries. On October 22, SK Networks, part of SK Group which is among the largest conglomerates in South Korea, hosted senior executives from Sunway, led by Group CEO of Digital and Strategic Investments Evan Cheah, to formalise this collaboration through an MoU signing ceremony at SK Networks' headquarters in the Samil Building, Jongno-gu, Seoul. SK Networks President & COO Sunghwan Choi(right) and Sunway Group CEO of Digital and Strategic Investments Evan Cheah attended the MoU ceremony between SK Networks and Sunway Group. Founded in 1974, Sunway today owns and manages three publicly-listed companies on Bursa Malaysia with a combined market capitalisation of more than RM35 billion / USD 8 billion, operating across 13 business divisions in 50 locations worldwide. Sunway is highly regarded for its unique build-own-operate model, and its flagship Sunway City Kuala Lumpur is Malaysia's first fully integrated, green and sustainable township, which attracts more than 42 million visits a year. SK Magic, a subsidiary of SK Networks specialising in innovative home appliances, has already established a foothold in the Malaysian market through its existing relationship with Sunway. This MoU will deepen this partnership by identifying key areas to leverage synergies across multiple business sectors and regions where SK Networks and Sunway have a presence. These initiatives include SK Magic's ongoing development of innovative AI-powered products and the introduction of PhnyX Lab's technology to develop and integrate AI systems within Sunway's ecosystem. Furthermore, SK Networks and Sunway are pushing for various collaboration models, such as establishment of a joint venture between SK Magic and Sunway, and possible share swap between SK Networks and Sunway. Sunway Group CEO of Digital and Strategic Investments Evan Cheah said: "Our partnership with an AI-driven organization like SK Networks represents a natural synergy for Sunway's own digital transformation journey." "As a conglomerate marking our 50th anniversary this year, we will continue to build on our history of embracing technology and innovation to evolve our businesses towards the next 50 years and beyond," Evan added. SK Networks plans to actively support the process following this agreement between the two companies to ensure that it translates into tangible results. The company aims to facilitate the smooth global expansion and collaboration of its existing businesses while continuing to enhance its value as an AI-driven company. Hojeong Lee, President & CEO of SK Networks said, "We will establish a working group to develop specific collaboration strategies with Sunway, focusing on AI-related areas. Our objective is to generate visible synergies as we expand our presence in Malaysia. We are dedicated to facilitating seamless operations between our headquarters and subsidiaries while also exploring innovative avenues to identify new business models and nurture external partnerships that can create significant value."
HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details. Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 DiabetesOctober 15, 2024, Germantown, MD. Seraxis Inc., a clinical stage regenerative medicine company invested by Viva BioInnovator (VBI), has received FDA's allowance of an Investigational New Drug (IND) application for a Phase I/II clinical study of its novel islet replacement therapy SR-02. SR-02 is the first reprogrammed stem cell-derived pancreatic product candidate allowed by FDA for testing in humans as a potential functional cure for insulin-requiring diabetes. Arthrosi Therapeutics and ApicHope Pharmaceutical Co-developed Gout Treatment AR882 Achieves Promising Phase II Clinical Results in China and Granted Fast Track Designation by the FDA According to ApicHope Pharmaceutical, Arthrosi Therapeutics, Inc. ("Arthrosi"), a portfolio company incubated by Viva Biotech, has achieved outstanding results in a Phase II clinical trial for the investigational gout treatment AR882. Developed in collaboration with ApicHope Pharmaceutical, this Class I novel drug showed promising outcomes for treating primary gout with hyperuricemia and has now entered Phase II clinical trials in China. The Phase II clinical trial primarily aimed to explore the optimal dosing of AR882 capsules for treating primary gout with hyperuricemia and to preliminarily assess the drug's efficacy and safety. The primary endpoint was the percentage of patients with serum uric acid levels below 360 μmol/L after eight weeks of treatment. By week six, AR882 demonstrated significant efficacy, with the 75mg dose of AR882 showing superiority over Febuxostat (P<0.001). AR882 exhibited an excellent safety profile, with no severe adverse events reported. Mild to moderate side effects observed included diarrhea, headache, and upper respiratory infections. Importantly, AR882 did not interfere with the management of patients' comorbidities, which remained stable throughout the trial. On August 19, Arthrosi Therapeutics announced that it received FDA Fast Track Designation for AR882 in Tophaceous Gout. Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687Copenhagen, Denmark – October 9, 2024 – Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity and invested and incubated by Viva BioInnovator (VBI), announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its lead molecule, AT-7687. This milestone enables Antag Therapeutics to initiate its Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and healthy obese subjects. The study will also explore AT-7687 as a monotherapy and in combination with semaglutide, a GLP-1 receptor agonist, in healthy obese individuals. Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian CancerNEW HAVEN, Conn. – October 7, 2024 – Cybrexa Therapeutics, invested and incubated by Viva BioInnovator (VBI), a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics, announced that the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in patients with platinum-resistant or refractory ovarian cancer. CBX-12 is a first-in-class PDC that uses Cybrexa's proprietary alphalex™ technology to enhance the delivery of exatecan, a potent, established topoisomerase 1 (TOP1) inhibitor, directly to tumor cells while sparing healthy tissue. This trial initiation follows promising Phase 1 results, which demonstrated CBX-12's broad activity across ovarian, breast, non-small cell lung cancer (NSCLC), thymic, gallbladder, and colorectal cancers, along with a manageable safety profile. Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic StrokeColumbus, Ohio – Sept. 10, 2024 – Basking Biosciences (Basking), invested and incubated by Viva BioInnovator (VBI), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, announced that the first patients have been dosed in RAISE, a Phase 2 clinical trial evaluating BB-031 in patients presenting with acute ischemic stroke (AIS). HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA PlatformLAUSANNE, Switzerland & SAN DIEGO, HAYA Therapeutics, SA, invested and incubated by Viva BioInnovator (VBI), a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply HAYA's advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions. Under the terms of the collaboration, HAYA will receive an upfront payment, including an equity investment, and is eligible to receive up to an aggregate $1 billion in pre-clinical, clinical and commercial milestone payments, as well as royalties on product sales. About SeraxisSeraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis' lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis. Visit www.seraxis.com. About ArthrosiArthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing AR882, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout. In the U.S., an estimated 13 million individuals are diagnosed with gout and approximately 2 million of those patients have visible tophi. In Phase II studies, AR882 demonstrated encouraging efficacy and safety compared to standard of care (SOC), while Phase IIb results showed impressive success in the complete elimination of tophi. Arthrosi is currently advancing AR882 into Phase III clinical trials. About Antag TherapeuticsAntag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. For more information, please visit https://antagtherapeutics.com. About Cybrexa TherapeuticsCybrexa is a privately held clinical-stage biotechnology company pioneering novel antigen-independent, tumor-targeting peptide-drug conjugate (PDC) therapeutics. The company is led by a dynamic team of highly successful life science entrepreneurs and veteran drug development scientists. Cybrexa is on a mission to create therapeutics that revolutionize the standard of care in oncology, and its robust pipeline aims to combat breast, ovarian, non-small cell lung cancer, and a range of other tumors. Its assets are built on Cybrexa's alphalex™ technology platform, which enables intracellular delivery of highly potent anti-cancer treatments. Cybrexa is based in New Haven, Connecticut and was founded in 2017. For more information, please visit www.cybrexa.com or follow us on LinkedIn and X. About Basking BiosciencesBasking Biosciences, a clinical-stage biopharmaceutical company, was founded to solve the biggest need in acute thrombosis – for a rapid-onset, short-acting thrombolytic drug capable of reopening blocked arteries, and whose activity can be quickly reversed in the event of a bleeding complication. Leveraging RNA aptamer technology, our lead drug candidate, BB-031, targets von Willebrand Factor (vWF), an important structural component of blood clots and driver of the clotting process, and is designed to be safer, more effective, and able to significantly expand the population receiving acute revascularization therapy. About HAYA TherapeuticsHAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
